Serum levels of LIGHT in MS

Multiple Sclerosis Journal

Volumn 19, Issue 7, 2013, Pages 871-876

  Malmeström, Clas ^a   Gillett, Alan ^b   Jernås, Margareta ^a   Khademi, Mohsen ^b   Axelsson, Markus ^a   Kockum, Ingrid ^b   Mattsson, Niklas ^a   Zetterberg, Henrik ^a   Blennow, Kaj ^a   Alfredsson, Lars ^b   Wadenvik, Hans ^a   Lycke, Jan ^a   Olsson, Tomas ^b   Olsson, Bob ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

LIGHT; Multiple sclerosis; natalizumab; relapsing remitting; serum

Indexed keywords

HERPESVIRUS ENTRY MEDIATOR LIGAND; LIGHT PROTEIN; NATALIZUMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; TREATMENT RESPONSE;

EID: 84878375851     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512463766     Document Type: Article

References (24)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 ; 372: 1502-1517
2. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
3. Mauri DN, Ebner R, Montgomery RI, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity. 1998 ; 8: 21-30
4. Harrop JA, McDonnell PC, Brigham-Burke M, et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem. 1998 ; 273: 27548-27556
5. Zhai Y, Guo R, Hsu TL, et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest. 1998 ; 102: 1142-1151
6. Morel Y, Schiano de, Colella JM, Harrop J, et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol. 2000 ; 165: 4397-4404
7. Scheu S, Alferink J, Potzel T, et al. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med. 2002 ; 195: 1613-1624
8. Tamada K, Shimozaki K, Chapoval AI, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med. 2000 ; 6: 283-289
9. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
11. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
12. Hedstrom AK, Baarnhielm M, Olsson T, et al. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology. 2009 ; 73: 696-701
13. Soroosh P, Doherty TA, So T, et al. Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations. J Exp Med. 2011 ; 208: 797-809
14. Shaikh RB, Santee S, Granger SW, et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol. 2001 ; 167: 6330-6337
15. Wang J, Anders RA, Wang Y, et al. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J Immunol. 2005 ; 174: 8173-8182
16. Wang J, Lo JC, Foster A, et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest. 2001 ; 108: 1771-1780
17. Cheung TC, Oborne LM, Steinberg MW, et al. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. J Immunol. 2009 ; 183: 7286-7296
18. Cheung TC, Steinberg MW, Oborne LM, et al. Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc Natl Acad Sci U S A. 2009 ; 106: 6244-6249
19. Cheung TC, Humphreys IR, Potter KG, et al. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci U S A. 2005 ; 102: 13,218-13,223
20. Shui JW, Steinberg MW, Kronenberg M. Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. J Leukoc Biol. 2011 ; 89: 517-523
21. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 ; 356: 63-66
22. Baron JL, Madri JA, Ruddle NH, et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993 ; 177: 57-68
23. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 ; 348: 15-23
24. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910